1Lips P (2006) Vitamin D physiology. Prog Biophys Mol Biol 92, 4–8.
2Lips P (2007) Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol 103, 620–625.
3Hewison M (2008) Vitamin D and innate immunity. Curr Opin Investig Drugs 9, 485–490.
4van Driel M, Koedam M, Buurman CJ, et al. (2006) Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 20, 2417–2419.
5McCann JC & Ames BN (2008) Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 22, 982–1001.
6Holick MF (2007) Vitamin D deficiency. N Engl J Med 357, 266–281.
7Anderson PH, Sawyer RK, Moore AJ, et al. (2008) Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J Bone Miner Res 23, 1789–1797.
8Gomez JM (2006) The role of insulin-like growth factor I components in the regulation of vitamin D. Curr Pharm Biotechnol 7, 125–132.
9Gallagher JC, Riggs BL & DeLuca HF (1980) Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab 51, 1359–1364.
10Christakos S, Dhawan P, Benn B, et al. (2007) Vitamin D: molecular mechanism of action. Ann N Y Acad Sci 1116, 340–348.
11Hewison M, Zehnder D, Bland R, et al. (2000) 1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol 25, 141–148.
12Somjen D, Weisman Y, Kohen F, et al. (2005) 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111, 1666–1671.
13Zehnder D, Bland R, Williams MC, et al. (2001) Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86, 888–894.
14Somjen D, Katzburg S, Stern N, et al. (2007) 25 Hydroxy-vitamin D(3)-1alpha hydroxylase expression and activity in cultured human osteoblasts and their modulation by parathyroid hormone, estrogenic compounds and dihydrotestosterone. J Steroid Biochem Mol Biol 107, 238–244.
15Anderson PH, O'Loughlin PD, May BK, et al. (2005) Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 36, 654–662.
16Chang Q, Hoefs S, van der Kemp AW, et al. (2005) The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310, 490–493.
17Yamashita T, Yoshioka M & Itoh N (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277, 494–498.
18Lanske B & Razzaque MS (2007) Mineral metabolism and aging: the fibroblast growth factor 23 enigma. Curr Opin Nephrol Hypertens 16, 311–318.
19Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117, 4003–4008.
20Shimada T, Hasegawa H, Yamazaki Y, et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19, 429–435.
21Urakawa I, Yamazaki Y, Shimada T, et al. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770–774.
22Nabeshima Y & Imura H (2008) alpha-Klotho: a regulator that integrates calcium homeostasis. Am J Nephrol 28, 455–464.
23Lanske B & Razzaque MS (2007) Vitamin D and aging: old concepts and new insights. J Nutr Biochem 18, 771–777.
24Holden JM, Lemar LE & Exler J (2008) Vitamin D in foods: development of the US Department of Agriculture database. Am J Clin Nutr 87, 1092S–1096S.
25Yetley EA (2008) Assessing the vitamin D status of the US population. Am J Clin Nutr 88, 558S–564S.
26Chel V, Wijnhoven HA, Smit JH, et al. (2008) Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int 19, 663–671.
27Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22, 477–501.
28Gallacher SJ, McQuillian C, Harkness M, et al. (2005) Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures. Curr Med Res Opin 21, 1355–1361.
29Hintzpeter B, Mensink GB, Thierfelder W, et al. (2008) Vitamin D status and health correlates among German adults. Eur J Clin Nutr 62, 1079–1089.
30Holick MF, Siris ES, Binkley N, et al. (2005) Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90, 3215–3224.
31Kuriacose R & Olive KE (2008) Prevalence of vitamin D deficiency and insufficiency in northeast Tennessee. South Med J 101, 906–909.
32Calvo MS, Whiting SJ & Barton CN (2005) Vitamin D intake: a global perspective of current status. J Nutr 135, 310–316.
33MacLaughlin J & Holick MF (1985) Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 76, 1536–1538.
34Holick MF & Chen TC (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87, 1080S–1086S.
35Holick MF, Matsuoka LY & Wortsman J (1989) Age, vitamin D, and solar ultraviolet. Lancet ii, 1104–1105.
36Adami S, Giannini S, Bianchi G et al. (2008) Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int .
37Konradsen S, Ag H, Lindberg F, et al. (2008) Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. Eur J Nutr 47, 87–91.
38Snijder MB, van Dam RM, Visser M, et al. (2005) Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab 90, 4119–4123.
39Lau KH & Baylink DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65, 295–306.
40Dukas LC, Schacht E, Mazor Z, et al. (2005) A new significant and independent risk factor for falls in elderly men and women: a low creatinine clearance of less than 65 ml/min. Osteoporos Int 16, 332–338.
41Thorner MO & Nass R (2007) Human studies of growth hormone and aging. Pediatr Endocrinol Rev 4, 233–234.
42Matkovits T & Christakos S (1995) Variable in vivo regulation of rat vitamin D-dependent genes (osteopontin, Ca,Mg-adenosine triphosphatase, and 25-hydroxyvitamin D3 24-hydroxylase): implications for differing mechanisms of regulation and involvement of multiple factors. Endocrinology 136, 3971–3982.
43Armbrecht HJ & Boltz MA (1991) Expression of 25-hydroxyvitamin D 24-hydroxylase cytochrome P450 in kidney and intestine. Effect of 1,25-dihydroxyvitamin D and age. FEBS Lett 292, 17–20.
44Bikle DD (2007) What is new in vitamin D: 2006–2007. Curr Opin Rheumatol 19, 383–388.
45Shah S, Islam MN, Dakshanamurthy S, et al. (2006) The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 21, 799–809.
46van Driel M, Koedam M, Buurman CJ, et al. (2006) Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. J Cell Biochem 99, 922–935.
47Duque G, El Abdaimi K, Macoritto M, et al. (2002) Estrogens (E2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: changes with aging and hormone deprivation. Biochem Biophys Res Commun 299, 446–454.
48Walters JR, Balesaria S, Chavele KM, et al. (2006) Calcium channel TRPV6 expression in human duodenum: different relationships to the vitamin D system and aging in men and women. J Bone Miner Res 21, 1770–1777.
49Bischoff-Ferrari HA, Borchers M, Gudat F, et al. (2004) Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 19, 265–269.
50Welsh J, Wietzke JA, Zinser GM, et al. (2002) Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 83, 85–92.
51Klaus G, Weber L, Rodriguez J, et al. (1998) Interaction of IGF-I and 1 alpha, 25(OH)2D3 on receptor expression and growth stimulation in rat growth plate chondrocytes. Kidney Int 53, 1152–1161.
52Andress D (2007) Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 67, 1999–2012.
53Fernandez-Martin JL, Kurian S, Farmer P, et al. (1998) Tumor necrosis factor activates a nuclear inhibitor of vitamin D and retinoid-X receptors. Mol Cell Endocrinol 141, 65–72.
54Gonzalez Pardo V, Boland R & de Boland AR (2008) Vitamin D receptor levels and binding are reduced in aged rat intestinal subcellular fractions. Biogerontology 9, 109–118.
55Vecino-Vecino C, Gratton M, Kremer R, et al. (2006) Seasonal variance in serum levels of vitamin D determines a compensatory response by parathyroid hormone: study in an ambulatory elderly population in Quebec. Gerontology 52, 33–39.
56Bjorkman MP, Sorva AJ & Tilvis RS (2008) Elevated serum parathyroid hormone predicts impaired survival prognosis in a general aged population. Eur J Endocrinol 158, 749–753.
57Perez AV, Picotto G, Carpentieri AR, et al. (2008) Minireview on regulation of intestinal calcium absorption. Emphasis on molecular mechanisms of transcellular pathway. Digestion 77, 22–34.
58Visser M, Deeg DJ & Lips P (2003) Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 88, 5766–5772.
59Rashid G, Bernheim J, Green J, et al. (2007) Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 292, F1215–F1218.
60Bullamore JR, Wilkinson R, Gallagher JC, et al. (1970) Effect of age on calcium absorption. Lancet ii, 535–537.
61Bianco SD, Peng JB, Takanaga H, et al. (2007) Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J Bone Miner Res 22, 274–285.
62Hoenderop JG, van der Kemp AW, Urben CM, et al. (2004) Effects of vitamin D compounds on renal and intestinal Ca2+ transport proteins in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice. Kidney Int 66, 1082–1089.
63Song Y, Kato S & Fleet JC (2003) Vitamin D receptor (VDR) knockout mice reveal VDR-independent regulation of intestinal calcium absorption and ECaC2 and calbindin D9k mRNA. J Nutr 133, 374–380.
64Armbrecht HJ, Boltz MA & Kumar VB (1999) Intestinal plasma membrane calcium pump protein and its induction by 1,25(OH)(2)D(3) decrease with age. Am J Physiol 277, G41–G47.
65Nordin BE, Need AG, Morris HA, et al. (2004) Effect of age on calcium absorption in postmenopausal women. Am J Clin Nutr 80, 998–1002.
66Scopacasa F, Wishart JM, Horowitz M, et al. (2004) Relation between calcium absorption and serum calcitriol in normal men: evidence for age-related intestinal resistance to calcitriol. Eur J Clin Nutr 58, 264–269.
67van Abel M, Huybers S, Hoenderop JG, et al. (2006) Age-dependent alterations in Ca2+ homeostasis: role of TRPV5 and TRPV6. Am J Physiol Renal Physiol 291, F1177–F1183.
68Hoenderop JG, Nilius B & Bindels RJ (2005) Calcium absorption across epithelia. Physiol Rev 85, 373–422.
69Lewin E & Olgaard K (2006) Klotho, an important new factor for the activity of Ca2+ channels, connecting calcium homeostasis, ageing and uraemia. Nephrol Dial Transplant 21, 1770–1772.
70Witkowski JM, Soroczynska-Cybula M, Bryl E, et al. (2007) Klotho – a common link in physiological and rheumatoid arthritis-related aging of human CD4+ lymphocytes. J Immunol 178, 771–777.
71Duce JA, Podvin S, Hollander W, et al. (2008) Gene profile analysis implicates klotho as an important contributor to aging changes in brain white matter of the rhesus monkey. Glia 56, 106–117.
72Nabeshima Y (2006) Toward a better understanding of klotho. Sci Aging Know Environ 8, pe11.
73Hoenderop JG, van Leeuwen JP, van der Eerden BC, et al. (2003) Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 112, 1906–1914.
74Torres PU, Prie D, Molina-Bletry V, et al. (2007) Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 71, 730–737.
75Renkema KY, Nijenhuis T, van der Eerden BC, et al. (2005) Hypervitaminosis D mediates compensatory Ca2+ hyperabsorption in TRPV5 knockout mice. J Am Soc Nephrol 16, 3188–3195.
76Worcester EM & Coe FL (2008) New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 28, 120–132.
77Russo de Boland A (2004) Age-related changes in the response of intestinal cells to parathyroid hormone. Mech Ageing Dev 125, 877–888.
78Massheimer V, Picotto G, Boland R, et al. (2000) Effect of aging on the mechanisms of PTH-induced calcium influx in rat intestinal cells. J Cell Physiol 182, 429–437.
79Zerwekh JE (2008) Blood biomarkers of vitamin D status. Am J Clin Nutr 87, 1087S–1091S.
80Bjorkman M, Sorva A & Tilvis R (2008) Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Arch Gerontol Geriatr .
81Adami S, Viapiana O, Gatti D, et al. (2008) Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone 42, 267–270.
82Vieth R, Ladak Y & Walfish PG (2003) Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 88, 185–191.
83Lips P (2004) Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 89–90, 611–614.
84Heaney RP (2005) The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 97, 13–19.
85Boonen S, Lips P, Bouillon R, et al. (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92, 1415–1423.
86Branca F & Valtuena S (2001) Calcium, physical activity and bone health-building bones for a stronger future. Public Health Nutr 4, 117–123.
87Visser M, Deeg DJ, Puts MT, et al. (2006) Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 84, 616–622.
88Richart T, Li Y & Staessen JA (2007) Renal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and hypertension. Am J Hypertens 20, 1007–1015.
89Giovannucci E (2008) Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 624, 31–42.
90Duque G & Troen BR (2008) Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric syndrome. J Am Geriatr Soc 56, 935–941.
91Kimball S, Fuleihan Gel H & Vieth R (2008) Vitamin D: a growing perspective. Crit Rev Clin Lab Sci 45, 339–414.
92Bouillon R, Verstuyf A, Mathieu C, et al. (2006) Vitamin D resistance. Best Pract Res Clin Endocrinol Metab 20, 627–645.
93Semba RD, Garrett E, Johnson BA, et al. (2000) Vitamin D deficiency among older women with and without disability. Am J Clin Nutr 72, 1529–1534.
94Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84, 18–28.
95Himmelstein S, Clemens TL, Rubin A, et al. (1990) Vitamin D supplementation in elderly nursing home residents increases 25(OH)D but not 1,25(OH)2D. Am J Clin Nutr 52, 701–706.
96Schleithoff SS, Zittermann A, Tenderich G, et al. (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83, 754–759.
97Stefikova K, Chylova K, Krivosikova Z et al. (2004) Intensive vitamin D supplementation in the treatment of osteoporosis. Vnitr Lek 50, 286–290.
98Health Council of The Netherlands (2008) Naar een toereikende inname van vitamine D (Towards an adequate intake of vitamin D). .
99Holick MF, Biancuzzo RM, Chen TC, et al. (2008) Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 93, 677–681.
100Blank S, Scanlon KS, Sinks TH, et al. (1995) An oubtreak of hypervitaminosis D associated with the overfortification of milk from a home-delivery dairy. Am J Public Health 5, 656–659.
101Hathcock JN, Shao A, Vieth R, et al. (2007) Risk assessment for vitamin D. Am J Clin Nutr 85, 6–18.
102Tsujikawa H, Kurotaki Y, Fujimori T, et al. (2003) Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17, 2393–2403.
103Shimada T, Kakitani M, Yamazaki Y, et al. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113, 561–568.
104Razzaque MS & Lanske B (2006) Hypervitaminosis D and premature aging: lessons learned from Fgf23 and klotho mutant mice. Trends Mol Med 12, 298–305.
105Jacobus CH, Holick MF, Shao Q, et al. (1992) Hypervitaminosis D associated with drinking milk. N Engl J Med 326, 1173–1177.
106Adams JS & Lee G (1997) Gains in bone mineral density with resolution of vitamin D intoxication. Ann Intern Med 127, 203–206.
107Avila E, Diaz L, Barrera D, et al. (2007) Regulation of vitamin D hydroxylases gene expression by 1,25-dihydroxyvitamin D3 and cyclic AMP in cultured human syncytiotrophoblasts. J Steroid Biochem Mol Biol 103, 90–96.
108Schauber J, Dorschner RA, Coda AB, et al. (2007) Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 117, 803–811.
109Bikle DD, Pillai S, Gee E, et al. (1989) Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology 124, 655–660.
110Xie Z, Munson SJ, Huang N, et al. (2002) The mechanism of 1,25-dihydroxyvitamin D(3) autoregulation in keratinocytes. J Biol Chem 277, 36987–36990.
111Bikle DD, Pillai S, Gee E, et al. (1991) Tumor necrosis factor-alpha regulation of 1,25-dihydroxyvitamin D production by human keratinocytes. Endocrinology 129, 33–38.
112Bikle DD, Nemanic MK, Gee E, et al. (1986) 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J Clin Invest 78, 557–566.
113Dusso AS, Finch J, Brown A, et al. (1991) Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72, 157–164.
114Stoffels K, Overbergh L, Giulietti A, et al. (2006) Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res 21, 37–47.
115Koeffler HP, Reichel H, Bishop JE, et al. (1985) gamma-Interferon stimulates production of 1,25-dihydroxyvitamin D3 by normal human macrophages. Biochem Biophys Res Commun 127, 596–603.
116Young MV, Schwartz GG, Wang L, et al. (2004) The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25, 967–971.
117Wang L, Flanagan JN, Whitlatch LW, et al. (2004) Regulation of 25-hydroxyvitamin D-1alpha-hydroxylase by epidermal growth factor in prostate cells. J Steroid Biochem Mol Biol 89–90, 127–130.
118Farhan H, Wahala K & Cross HS (2003) Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 84, 423–429.
119Theodoropoulos C, Demers C, Delvin E, et al. (2003) Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine. Clin Endocrinol (Oxf) 58, 489–499.
120Liu N, Nguyen L & Chun RF, et al. (2008) Altered endocrine and autocrine metabolism of vitamin D in a mouse model of gastrointestinal inflammation. Endocrinology .
121Kallay E, Bises G, Bajna E, et al. (2005) Colon-specific regulation of vitamin D hydroxylases – a possible approach for tumor prevention. Carcinogenesis 26, 1581–1589.
122Diesel B, Radermacher J, Bureik M, et al. (2005) Vitamin D(3) metabolism in human glioblastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol, and effect of calcitriol. Clin Cancer Res 11, 5370–5380.
123Zehnder D, Bland R, Chana RS, et al. (2002) Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13, 621–629.
124Kemmis CM, Salvador SM, Smith KM, et al. (2006) Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136, 887–892.
125Peng X, Hawthorne M & Vaishnav A (2008) 25-Hydroxyvitamin D(3) is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat .
126Cross HS, Kallay E & Lechner D (2004) Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J Nutr 134, 1207S–1212S.